Here's a look at some of the top regulatory stories for medical device companies this week: Seven questions raised by Medtronic's $43B Covidien acquisition; Medtronic, Covidien merger: Good or bad for medtech innovation?; Medtronic, Covidien merger: Mass. Gov. Deval Patrick says he's had no contact with either company; Volcano closes $117M AtheroMed buy; Incubator group buys prostate treatment tech from Endo Health.
Medtronic names Geoff Martha, its senior vice president for strategy & business development, as chief integration officer as it preps to digest the $43 billion Covidien acquisition.
Covidien launches its Pipeline Flex embolization system in European markets after landing CE Mark earlier this year.
Medtech giant Covidien (NYSE:COV) announced this week that it's prepared to launch its Pipeline Flex embolization devices in Europe.
Covidien files another patent infringement lawsuit against Johnson & Johnson's Ethicon Endo-Surgery division over ultrasound shears technology.
Medtech giants Medtronic and Covidien aren't likely to be very acquisitive after finalizing their $43 billion merger, taking 2 very important players out of the game for startup companies, venture capitalists say.
Here's a look at some of the top Wall Street stories for medical device companies this week: Blockbuster: Medtronic in $43B deal to acquire Covidien; Medtronic buyout holds $80M in golden parachutes for Covidien execs; FDA wants another panel hearing on Boston Scientific's Watchman anti-stroke device; European Commission tables review of Zimmer's $13B acquisition of Biomet; Ackman takes Allergan to court to defend against poison pill